ECM
BMRN icon

Element Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Element Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-84,170
Closed -$6.82M – 833
2018
Q1 		$6.82M Sell
84,170
-70,221
-45% -$6.03M 0.16% 101
2017
Q4 		$13.8M Buy
+154,391
New +$13.4M 0.28% 89

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Element Capital Management's BMRN Position: Q2 2018 in Review

Element Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2018, closing a stake of 84,170 shares — an estimated $6.82M sold.

Element Capital Management first reported a position in BMRN in Q4 2017 and held it in 2 quarters. The position peaked at $13.8M in Q4 2017. 448 funds tracked by Wall St. Rank hold BMRN as of Q2 2018.

  • Element Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Element Capital Management sold 84,170 BioMarin Pharmaceuticals shares in Q2 2018, an estimated $6.82M.
  • Element Capital Management first reported a position in BioMarin Pharmaceuticals in Q4 2017 and held it in 2 quarters.
  • Element Capital Management's BioMarin Pharmaceuticals position peaked at $13.8M in Q4 2017.
  • 448 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2018.

Based on Element Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.